ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

[cafead]

via Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming in the rear view mirror – armed with new data for its already-filed rival Tecartus.

article source